Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185875 | 0.81 | IDO1 (0.53) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL3507942 | 0.80 | IDO1 (0.57) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL185874 | 0.79 | IDO1 (0.55) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL3507940 | 0.78 | IDO1 (0.59) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL11791488 | 0.76 | IDO1 (0.61) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL28546168 | 0.75 | TSHR (0.44) | IDO1TSHRHIF1ACA12CA2 | |
| SCHEMBL29152360 | 0.72 | IDO1 (0.52) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL126999 | 0.71 | IDO1 (0.67) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL17766315 | 0.71 | IDO1 (0.39) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL30434974 | 0.69 | IDO1 (0.53) | IDO1HSPA5KEAP1TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683927-A1 | ALPHA-MODIFIED NUCLEOSIDE TRIPHOSPHATES AND METHOD FOR THEIR SYNTHESIS | Illumina, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| WO-2024196883-A1 | ALPHA-MODIFIED NUCLEOSIDE TRIPHOSPHATES AND METHOD FOR THEIR SYNTHESIS | ILLUMINA, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| EP-3110825-B1 | NOVEL SYNTHETIC OLIGOMERS OF NEISSERIA MENINGITIS SEROGROUP X AND PROCESS OF PREPARING THEM | MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT LTD (IN) | 2020-12-09 | — | — | EP | claimed |
| CN-106061986-B | Novel synthetic oligomers of neisseria meningitidis serogroup X and process for their preparation | 默沙东和惠康基金会合资的希勒曼实验室私人有限公司 | 2020-07-07 | — | — | CN | claimed |
| US-10183962-B2 | Synthetic oligomers of Neisseria meningitis serogroup X and process of preparing them | MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD. (IN) | 2019-01-22 | — | — | US | claimed |
| US-20170066794-A1 | NOVEL SYNTHETIC OLIGOMERS OF NEISSERIA MENINGITIS SEROGROUP X AND PROCESS OF PREPARING THEM | MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD. (IN) | 2017-03-09 | — | — | US | claimed |
| EP-3110825-A1 | NOVEL SYNTHETIC OLIGOMERS OF NEISSERIA MENINGITIS SEROGROUP X AND PROCESS OF PREPARING THEM | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. (IN) | 2017-01-04 | — | — | EP | claimed |
| WO-2015128797-A1 | NOVEL SYNTHETIC OLIGOMERS OF NEISSERIA MENINGITIS SEROGROUP X AND PROCESS OF PREPARING THEM | MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD. (IN) | 2015-09-03 | — | — | WO | claimed |
| EP-4683927-A1 | ALPHA-MODIFIED NUCLEOSIDE TRIPHOSPHATES AND METHOD FOR THEIR SYNTHESIS | Illumina, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | SINGULAR GENOMICS SYSTEMS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250346950-A1 | TAGGED NUCLEOSIDE COMPOUNDS USEFUL FOR NANOPORE DETECTION | Roche Sequencing Solutions, Inc. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12270075-B2 | Tagged nucleoside compounds useful for nanopore detection | Roche Sequencing Solutions, Inc. (US) | 2025-04-08 | — | — | US | disclosed |
| US-12215122-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-12195493-B2 | Reversibly blocked nucleoside analogues and their use | MGI TECH CO., LTD. (CN) | 2025-01-14 | — | — | US | disclosed |
| US-5204455-A | Monomethoxytrityl protected oligonucleotides bound to a solid support | ISIS PHARMACEUTICALS, INC. | 1993-04-20 | — | — | US | disclosed |
| US-5164491-A | Large scale synthesis of oligonucleotides and their associated analogs | GILEAD SCIENCES (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0241363-B1 | NUCLEOSIDE DERIVATIVES AND THEIR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1991-09-25 | — | — | EP | disclosed |
| EP-0438203-A2 | Nucleoside derivatives and their use in oligonucleotide synthesis | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1991-07-24 | — | — | EP | disclosed |
| US-4980460-A | Protected nucleosides which permit more efficient oligonucleotide syntheses | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1990-12-25 | — | — | US | disclosed |
| EP-0241363-A1 | Nucleoside derivatives and their use in the synthesis of oligonucleotides | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1987-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346950-A1 | TAGGED NUCLEOSIDE COMPOUNDS USEFUL FOR NANOPORE DETECTION | PNP, NT5C3B, POLN | IDO1 4654/4885HSPA5 4590/4885KEAP1 4679/4885 |
| US-12270075-B2 | Tagged nucleoside compounds useful for nanopore detection | NT5C3B, PNP, POLN | IDO1 4688/4885HSPA5 4473/4885KEAP1 4697/4885 |
| US-12215122-B2 | Nucleotide analogues | NUDT1, POLN, TYMP | IDO1 3909/4885HSPA5 2564/4885KEAP1 4512/4885 |
| US-20170066794-A1 | NOVEL SYNTHETIC OLIGOMERS OF NEISSERIA MENINGITIS SEROGROUP X AND PROCESS OF PREPARING THEM | MLEC, MEN1, MAN2B2 | IDO1 2127/4885HSPA5 4480/4885KEAP1 1563/4885 |
| US-12195493-B2 | Reversibly blocked nucleoside analogues and their use | NSUN2, NME2, ADAR | IDO1 4829/4885HSPA5 2216/4885KEAP1 4831/4885 |
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | ADAR, NUDT1, NSUN2 | IDO1 4209/4885HSPA5 2909/4885KEAP1 4579/4885 |
| US-10183962-B2 | Synthetic oligomers of Neisseria meningitis serogroup X and process of preparing them | MLEC, MEN1, MAN2B2 | IDO1 1749/4885HSPA5 4411/4885KEAP1 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.